Literature DB >> 20304841

Role of antiarrhythmic drugs in patients with implantable cardioverter defibrillators.

Hugo Van Herendael1, Arnold Pinter, Kamran Ahmad, Victoria Korley, Iqwal Mangat, Paul Dorian.   

Abstract

The transvenous implantable cardioverter defibrillator (ICD) has emerged as the primary therapy for patients at high risk of life-threatening ventricular arrhythmias. A high number of ICD recipients will require subsequent adjunctive treatment with antiarrhythmic drugs (AADs). This review provides an overview of potential reasons for AAD initiation, candidates for treatment, current medical options, and possible drug-device interactions.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20304841     DOI： 10.1093/europace/euq073

Source DB:  PubMed          Journal:  Europace        ISSN： 1099-5129            Impact factor:   5.214


  8 in total

Review 1.  [Incessant or recurrent ventricular tachycardia. Indications for emergency ablation].

Authors:  R Surber; D Prochnau; H Kühnert; H R Figulla
Journal:  Med Klin Intensivmed Notfmed       Date:  2012-04-22       Impact factor: 0.840

Review 2.  Electrical Storm: Current Evidence, Clinical Implications, and Future Perspectives.

Authors:  Christos Kontogiannis; Konstantinos Tampakis; Georgios Georgiopoulos; Stefano Bartoletti; Christos Papageorgiou; Hector Anninos; Alkistis Kapelouzou; Michael Spartalis; Ioannis Paraskevaidis; Sofia Chatzidou
Journal:  Curr Cardiol Rep       Date:  2019-07-27       Impact factor: 2.931

3.  The Significance of Shocks in Implantable Cardioverter Defibrillator Recipients.

Authors:  Anthony Li; Amit Kaura; Nicholas Sunderland; Paramdeep S Dhillon; Paul A Scott
Journal:  Arrhythm Electrophysiol Rev       Date:  2016-08

Review 4.  Ventricular Tachycardia with ICD Shocks: When to Medicate and When to Ablate.

Authors:  Amir AbdelWahab; John Sapp
Journal:  Curr Cardiol Rep       Date:  2017-09-13       Impact factor: 2.931

5.  Effect of spironolactone on ventricular arrhythmias in patients with left ventricular systolic dysfunction and implantable cardioverter defibrillators.

Authors:  Abdul Wase; Naga Garikipati; Omar Mufti; Zulfiqar Mirza; Aparna Innaparthy; Anwarul Kabir; Mohammed B Quraishi; Ronald Markert
Journal:  Indian Heart J       Date:  2012-04-28

6.  Current and emerging antiarrhythmic drug therapy for ventricular tachycardia.

Authors:  Eric S Williams; Mohan N Viswanathan
Journal:  Cardiol Ther       Date:  2013-02-20

7.  Amiodarone-induced thyrotoxicosis in heart failure with a reduced ejection fraction: A retrospective cohort study.

Authors:  Jennifer M Yamamoto; Pamela M Katz; James A F Bras; Leigh Anne Shafer; Alexander A Leung; Amir Ravandi; Francisco J Cordova
Journal:  Health Sci Rep       Date:  2018-04-16

Review 8.  The Increment of Short-term Variability of Repolarisation Determines the Severity of the Imminent Arrhythmic Outcome.

Authors:  Agnieszka Smoczynska; Henriëtte Dm Beekman; Marc A Vos
Journal:  Arrhythm Electrophysiol Rev       Date:  2019-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.